REDWOOD CITY, Calif.–(January 6, 2017)–Atreca, Inc., a biotechnology company
focused on developing novel therapeutics based on a deep understanding of the human
immune response, announced today that Tito A. Serafini, Ph.D., Atreca’s President,
Chief Executive Officer, and CoFounder, will participate in a panel discussion on
immuno-oncology (IO) during the 9th Annual Biotech Showcase Conference on
Wednesday, January 11, 2017, at 11:00a.m. Pacific Time.
The panel, titled “The Overflowing IO Buffet: Next Gen IO Antibodies, Oncolytic Viruses,
Bispecifics, Adoptive Cell Therapies and Oral Immunometabolism / Immuno-Epigenetic
Agents,” will be held at the Hilton San Francisco Union Square in Continental Room 2.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn
from human immune responses, including effective anti-cancer immune responses. We
are able to measure and analyze the structure of clinically relevant immune responses
to identify the antibodies, T cell receptors, and targets that are key to successful
treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® technology
profiles a patient’s immune response at the single-cell level at very high throughput
without bias or error, enabling the identification and generation of functional human
antibodies and TCRs without prior knowledge of antigen. The Company is advancing a
pipeline of candidates with the objective of enhancing engagement of the human
immune response in cancer treatment and other indications, thus optimizing therapeutic
outcomes. For more information on Atreca, please visit www.atreca.com.